secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evoke Pharma Inc (—)
CIK:        0001403708
Form:       8-K
Filed at:   2024-03-25T23:59:59+00:00
Accession:  0000950170-24-035987
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evoke Pharma amends Series B/C warrants to accelerate vesting, allow pre-funded warrants
--------------------------------------------------------------------------------

- Series C warrants become exercisable for up to 3x Series B shares exercised before March 27, 2024 deadline.
- After deadline, remaining Series B exercises trigger one-for-one vesting of Series C warrants.
- Holders may elect pre-funded warrants at exercise price of $0.6799 per share instead of common stock.
- No change to total number of warrant shares underlying each series.
- Company will allow other holders to enter identical amendment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1403708/000095017024035987/0000950170-24-035987-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1403708/000095017024035987/evok-20240325.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-035987

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer